CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

This study tests CT0594CP, a type of CAR-T cell therapy — where a patient's own immune cells are genetically engineered to attack cancer cells — for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to previous treatments. CAR-T therapy is a cutting-edge approach that reprograms the immune system to fight blood cancers. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with multiple myeloma or plasma cell leukemia - Your cancer has relapsed or become resistant after prior treatment - Your cancer is measurable (detectable levels of abnormal protein in blood or urine) - Your overall health is acceptable (ECOG 0–2) **You may NOT be eligible if...** - You have active serious infections or uncontrolled illnesses - You have had prior CAR-T cell therapy or allogeneic stem cell transplant - Your major organs (heart, liver, kidneys, lungs) are not functioning adequately - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.